Skip to main content
Erschienen in: Alzheimer's Research & Therapy 4/2013

01.08.2013 | Review

Regulation of distinct pools of amyloid β-protein by multiple cellular proteases

verfasst von: Malcolm A Leissring, Anthony J Turner

Erschienen in: Alzheimer's Research & Therapy | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Alzheimer’s disease (AD) is a progressive, age-related neurodegenerative disorder characterized by extracellular and intracellular deposition of the amyloid β-protein (Aβ). The study of rare, familial forms of AD has shown that sustained elevations in the production of Aβ (either all forms or specific pathogenic variants thereof) are sufficient to trigger the full spectrum of cognitive and histopathological features of the disease. Although the exact cause or causes remain unknown, emerging evidence suggests that impairments in the clearance of Aβ, after it is produced, may underlie the vast majority of sporadic AD cases. This review focuses on Aβ-degrading proteases (AβDPs), which have emerged as particularly important mediators of Aβ clearance. A wide variety of proteases that – by virtue of their particular regional and subcellular localization profiles – define distinct pools of Aβ have been identified. Different pools of Aβ, in turn, may contribute differentially to the pathogenesis of the disease. The study of individual AβDPs, therefore, promises to offer new insights into the mechanistic basis of AD pathogenesis and, ultimately, may facilitate the development of effective methods for its prevention or treatment or both.
Literatur
1.
Zurück zum Zitat Selkoe DJ: The origins of Alzheimer disease: a is for amyloid. JAMA. 2000, 283: 1615-1617. 10.1001/jama.283.12.1615.CrossRefPubMed Selkoe DJ: The origins of Alzheimer disease: a is for amyloid. JAMA. 2000, 283: 1615-1617. 10.1001/jama.283.12.1615.CrossRefPubMed
2.
Zurück zum Zitat De Strooper B, Vassar R, Golde T: The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010, 6: 99-107. 10.1038/nrneurol.2009.218.PubMedCentralCrossRefPubMed De Strooper B, Vassar R, Golde T: The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010, 6: 99-107. 10.1038/nrneurol.2009.218.PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Vassar R: Beta-Secretase, APP and Abeta in Alzheimer’s disease. Subcell Biochem. 2005, 38: 79-103. 10.1007/0-387-23226-5_4.CrossRefPubMed Vassar R: Beta-Secretase, APP and Abeta in Alzheimer’s disease. Subcell Biochem. 2005, 38: 79-103. 10.1007/0-387-23226-5_4.CrossRefPubMed
4.
Zurück zum Zitat Selkoe DJ: Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature. 1999, 399: A23-A31.CrossRefPubMed Selkoe DJ: Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature. 1999, 399: A23-A31.CrossRefPubMed
5.
Zurück zum Zitat Walsh DM, Selkoe DJ: Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004, 11: 213-228. 10.2174/0929866043407174.CrossRefPubMed Walsh DM, Selkoe DJ: Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004, 11: 213-228. 10.2174/0929866043407174.CrossRefPubMed
6.
Zurück zum Zitat Citron M, Eckman CB, Diehl TS, Corcoran C, Ostaszewski BL, Xia W, Levesque G, St George Hyslop P, Younkin SG, Selkoe DJ: Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid beta-protein. Neurobiol Dis. 1998, 5: 107-116. 10.1006/nbdi.1998.0183.CrossRefPubMed Citron M, Eckman CB, Diehl TS, Corcoran C, Ostaszewski BL, Xia W, Levesque G, St George Hyslop P, Younkin SG, Selkoe DJ: Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid beta-protein. Neurobiol Dis. 1998, 5: 107-116. 10.1006/nbdi.1998.0183.CrossRefPubMed
7.
Zurück zum Zitat Vassar R, Citron M: Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron. 2000, 27: 419-422. 10.1016/S0896-6273(00)00051-9.CrossRefPubMed Vassar R, Citron M: Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron. 2000, 27: 419-422. 10.1016/S0896-6273(00)00051-9.CrossRefPubMed
8.
Zurück zum Zitat Saido T, Leissring MA: Proteolytic degradation of amyloid beta-protein. Cold Spring Harb Perspect Med. 2012, 2: a006379-10.1101/cshperspect.a006379.PubMedCentralCrossRefPubMed Saido T, Leissring MA: Proteolytic degradation of amyloid beta-protein. Cold Spring Harb Perspect Med. 2012, 2: a006379-10.1101/cshperspect.a006379.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Shinohara M, Petersen RC, Dickson DW, Bu G: Brain regional correlation of amyloid-beta with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-beta accumulation. Acta Neuropathol. 2013, 125: 535-547. 10.1007/s00401-013-1086-9.PubMedCentralCrossRefPubMed Shinohara M, Petersen RC, Dickson DW, Bu G: Brain regional correlation of amyloid-beta with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-beta accumulation. Acta Neuropathol. 2013, 125: 535-547. 10.1007/s00401-013-1086-9.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Belyaev ND, Kellett KA, Beckett C, Makova NZ, Revett TJ, Nalivaeva NN, Hooper NM, Turner AJ: The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway. J Biol Chem. 2010, 285: 41443-41454. 10.1074/jbc.M110.141390.PubMedCentralCrossRefPubMed Belyaev ND, Kellett KA, Beckett C, Makova NZ, Revett TJ, Nalivaeva NN, Hooper NM, Turner AJ: The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway. J Biol Chem. 2010, 285: 41443-41454. 10.1074/jbc.M110.141390.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Yamazaki T, Selkoe DJ, Koo EH: Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons. J Cell Biol. 1995, 129: 431-442. 10.1083/jcb.129.2.431.CrossRefPubMed Yamazaki T, Selkoe DJ, Koo EH: Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons. J Cell Biol. 1995, 129: 431-442. 10.1083/jcb.129.2.431.CrossRefPubMed
12.
Zurück zum Zitat Haass C, Hung AY, Selkoe DJ: Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion. J Neurosci. 1991, 11: 3783-3793.PubMed Haass C, Hung AY, Selkoe DJ: Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion. J Neurosci. 1991, 11: 3783-3793.PubMed
13.
Zurück zum Zitat Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA: Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A. 1993, 90: 2092-2096. 10.1073/pnas.90.5.2092.PubMedCentralCrossRefPubMed Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA: Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A. 1993, 90: 2092-2096. 10.1073/pnas.90.5.2092.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Thinakaran G, Koo EH: Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008, 283: 29615-29619. 10.1074/jbc.R800019200.PubMedCentralCrossRefPubMed Thinakaran G, Koo EH: Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008, 283: 29615-29619. 10.1074/jbc.R800019200.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Chyung JH, Raper DM, Selkoe DJ: Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. J Biol Chem. 2005, 280: 4383-4392.CrossRefPubMed Chyung JH, Raper DM, Selkoe DJ: Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. J Biol Chem. 2005, 280: 4383-4392.CrossRefPubMed
16.
Zurück zum Zitat Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR: Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000, 156: 15-20. 10.1016/S0002-9440(10)64700-1.PubMedCentralCrossRefPubMed Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR: Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000, 156: 15-20. 10.1016/S0002-9440(10)64700-1.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat LaFerla FM, Green KN, Oddo S: Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci. 2007, 8: 499-509. 10.1038/nrn2168.CrossRefPubMed LaFerla FM, Green KN, Oddo S: Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci. 2007, 8: 499-509. 10.1038/nrn2168.CrossRefPubMed
18.
Zurück zum Zitat Glabe C: Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer’s disease. J Mol Neurosci. 2001, 17: 137-145. 10.1385/JMN:17:2:137.CrossRefPubMed Glabe C: Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer’s disease. J Mol Neurosci. 2001, 17: 137-145. 10.1385/JMN:17:2:137.CrossRefPubMed
20.
Zurück zum Zitat Hansson CA, Frykman S, Farmery MR, Tjernberg LO, Nilsberth C, Pursglove SE, Ito A, Winblad B, Cowburn RF, Thyberg J, Ankarcrona M: Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J Biol Chem. 2004, 279: 51654-51660. 10.1074/jbc.M404500200.CrossRefPubMed Hansson CA, Frykman S, Farmery MR, Tjernberg LO, Nilsberth C, Pursglove SE, Ito A, Winblad B, Cowburn RF, Thyberg J, Ankarcrona M: Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J Biol Chem. 2004, 279: 51654-51660. 10.1074/jbc.M404500200.CrossRefPubMed
21.
Zurück zum Zitat Pavlov PF, Wiehager B, Sakai J, Frykman S, Behbahani H, Winblad B, Ankarcrona M: Mitochondrial gamma-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein. Faseb J. 2011, 25: 78-88. 10.1096/fj.10-157230.CrossRefPubMed Pavlov PF, Wiehager B, Sakai J, Frykman S, Behbahani H, Winblad B, Ankarcrona M: Mitochondrial gamma-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein. Faseb J. 2011, 25: 78-88. 10.1096/fj.10-157230.CrossRefPubMed
22.
Zurück zum Zitat Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG: Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res. 1998, 52: 691-698. 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3.CrossRefPubMed Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG: Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res. 1998, 52: 691-698. 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3.CrossRefPubMed
23.
Zurück zum Zitat Schmitz A, Schneider A, Kummer MP, Herzog V: Endoplasmic reticulum-localized amyloid beta-peptide is degraded in the cytosol by two distinct degradation pathways. Traffic. 2004, 5: 89-101. 10.1111/j.1600-0854.2004.00159.x.CrossRefPubMed Schmitz A, Schneider A, Kummer MP, Herzog V: Endoplasmic reticulum-localized amyloid beta-peptide is degraded in the cytosol by two distinct degradation pathways. Traffic. 2004, 5: 89-101. 10.1111/j.1600-0854.2004.00159.x.CrossRefPubMed
24.
Zurück zum Zitat Zhang Y, McLaughlin R, Goodyer C, LeBlanc A: Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol. 2002, 156: 519-529. 10.1083/jcb.200110119.PubMedCentralCrossRefPubMed Zhang Y, McLaughlin R, Goodyer C, LeBlanc A: Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol. 2002, 156: 519-529. 10.1083/jcb.200110119.PubMedCentralCrossRefPubMed
25.
Zurück zum Zitat Lee EK, Park YW, Shin DY, Mook-Jung I, Yoo YJ: Cytosolic amyloid-beta peptide 42 escaping from degradation induces cell death. Biochem Biophys Res Commun. 2006, 344: 471-477. 10.1016/j.bbrc.2006.03.166.CrossRefPubMed Lee EK, Park YW, Shin DY, Mook-Jung I, Yoo YJ: Cytosolic amyloid-beta peptide 42 escaping from degradation induces cell death. Biochem Biophys Res Commun. 2006, 344: 471-477. 10.1016/j.bbrc.2006.03.166.CrossRefPubMed
26.
Zurück zum Zitat Zlokovic BV: Cerebrovascular transport of Alzheimer’s amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sci. 1996, 59: 1483-1497. 10.1016/0024-3205(96)00310-4.CrossRefPubMed Zlokovic BV: Cerebrovascular transport of Alzheimer’s amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sci. 1996, 59: 1483-1497. 10.1016/0024-3205(96)00310-4.CrossRefPubMed
27.
Zurück zum Zitat Bu G: Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009, 10: 333-344. 10.1038/nrn2620.PubMedCentralCrossRefPubMed Bu G: Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009, 10: 333-344. 10.1038/nrn2620.PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Belbin O, Carrasquillo MM, Crump M, Culley OJ, Hunter TA, Ma L, Bisceglio G, Zou F, Allen M, Dickson DW, Graff-Radford NR, Petersen RC, Morgan K, Younkin SG: Investigation of 15 of the top candidate genes for late-onset Alzheimer’s disease. Hum Genet. 2011, 129: 273-282. 10.1007/s00439-010-0924-2.PubMedCentralCrossRefPubMed Belbin O, Carrasquillo MM, Crump M, Culley OJ, Hunter TA, Ma L, Bisceglio G, Zou F, Allen M, Dickson DW, Graff-Radford NR, Petersen RC, Morgan K, Younkin SG: Investigation of 15 of the top candidate genes for late-onset Alzheimer’s disease. Hum Genet. 2011, 129: 273-282. 10.1007/s00439-010-0924-2.PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Leissring MA: Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer’s disease. Curr Alzheimer Res. 2006, 3: 431-435. 10.2174/156720506779025206.CrossRefPubMed Leissring MA: Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer’s disease. Curr Alzheimer Res. 2006, 3: 431-435. 10.2174/156720506779025206.CrossRefPubMed
30.
Zurück zum Zitat Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ: Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?. J Neurochem. 2012, 120: 167-185.CrossRefPubMed Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ: Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?. J Neurochem. 2012, 120: 167-185.CrossRefPubMed
31.
Zurück zum Zitat Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L: Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer’s disease. Neuron. 2006, 51: 703-714. 10.1016/j.neuron.2006.07.027.CrossRefPubMed Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L: Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer’s disease. Neuron. 2006, 51: 703-714. 10.1016/j.neuron.2006.07.027.CrossRefPubMed
32.
Zurück zum Zitat Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, Gong JS, Yu W, Yamamoto T, Kosaka K, Yanagisawa K, Michikawa M: Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci. 2007, 27: 8628-8635. 10.1523/JNEUROSCI.1549-07.2007.CrossRefPubMed Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, Gong JS, Yu W, Yamamoto T, Kosaka K, Yanagisawa K, Michikawa M: Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci. 2007, 27: 8628-8635. 10.1523/JNEUROSCI.1549-07.2007.CrossRefPubMed
33.
Zurück zum Zitat Leissring MA, Reinstatler L, Sahara T, Roman R, Sevlever D, Saftig P, Levites Y, Golde TE, Burgess JD, Ertekin-Taner N, Eckman EA: Cathepsin D selectively degrades Aβ42 and tau: implications for Alzheimer disease pathogenesis. Society for Neuroscience. 2009, Chicago, IL: Society for Neuroscience, Program No. 139.108 Leissring MA, Reinstatler L, Sahara T, Roman R, Sevlever D, Saftig P, Levites Y, Golde TE, Burgess JD, Ertekin-Taner N, Eckman EA: Cathepsin D selectively degrades Aβ42 and tau: implications for Alzheimer disease pathogenesis. Society for Neuroscience. 2009, Chicago, IL: Society for Neuroscience, Program No. 139.108
34.
Zurück zum Zitat Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, Ladd TB, Das P, Dickson DW, Golde TE: Overlapping profiles of Abeta peptides in the Alzheimer’s disease and pathological aging brains. Alzheimers Res Ther. 2012, 4: 18-10.1186/alzrt121.PubMedCentralCrossRefPubMed Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, Ladd TB, Das P, Dickson DW, Golde TE: Overlapping profiles of Abeta peptides in the Alzheimer’s disease and pathological aging brains. Alzheimers Res Ther. 2012, 4: 18-10.1186/alzrt121.PubMedCentralCrossRefPubMed
35.
Zurück zum Zitat Walsh DM, Selkoe DJ: Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron. 2004, 44: 181-193. 10.1016/j.neuron.2004.09.010.CrossRefPubMed Walsh DM, Selkoe DJ: Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron. 2004, 44: 181-193. 10.1016/j.neuron.2004.09.010.CrossRefPubMed
36.
Zurück zum Zitat Grundke-Iqbal I, Iqbal K, George L, Tung YC, Kim KS, Wisniewski HM: Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci U S A. 1989, 86: 2853-2857. 10.1073/pnas.86.8.2853.PubMedCentralCrossRefPubMed Grundke-Iqbal I, Iqbal K, George L, Tung YC, Kim KS, Wisniewski HM: Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci U S A. 1989, 86: 2853-2857. 10.1073/pnas.86.8.2853.PubMedCentralCrossRefPubMed
37.
Zurück zum Zitat Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC: Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med. 2001, 125: 489-492.PubMed Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC: Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med. 2001, 125: 489-492.PubMed
38.
Zurück zum Zitat LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G: The Alzheimer’s A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet. 1995, 9: 21-30. 10.1038/ng0195-21.CrossRefPubMed LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G: The Alzheimer’s A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet. 1995, 9: 21-30. 10.1038/ng0195-21.CrossRefPubMed
39.
Zurück zum Zitat McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T: Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005, 47: 191-199. 10.1016/j.neuron.2005.06.030.PubMedCentralCrossRefPubMed McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T: Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005, 47: 191-199. 10.1016/j.neuron.2005.06.030.PubMedCentralCrossRefPubMed
40.
Zurück zum Zitat Lewis PA, Piper S, Baker M, Onstead L, Murphy MP, Hardy J, Wang R, McGowan E, Golde TE: Expression of BRI-amyloid beta peptide fusion proteins: a novel method for specific high-level expression of amyloid beta peptides. Biochim Biophys Acta. 2001, 1537: 58-62. 10.1016/S0925-4439(01)00054-0.CrossRefPubMed Lewis PA, Piper S, Baker M, Onstead L, Murphy MP, Hardy J, Wang R, McGowan E, Golde TE: Expression of BRI-amyloid beta peptide fusion proteins: a novel method for specific high-level expression of amyloid beta peptides. Biochim Biophys Acta. 2001, 1537: 58-62. 10.1016/S0925-4439(01)00054-0.CrossRefPubMed
41.
Zurück zum Zitat Sudoh S, Frosch MP, Wolf BA: Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry. 2002, 41: 1091-1099. 10.1021/bi011193l.CrossRefPubMed Sudoh S, Frosch MP, Wolf BA: Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry. 2002, 41: 1091-1099. 10.1021/bi011193l.CrossRefPubMed
42.
Zurück zum Zitat Hama E, Shirotani K, Iwata N, Saido TC: Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid beta peptide clearance in primary neurons. J Biol Chem. 2004, 279: 30259-30264. 10.1074/jbc.M401891200.CrossRefPubMed Hama E, Shirotani K, Iwata N, Saido TC: Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid beta peptide clearance in primary neurons. J Biol Chem. 2004, 279: 30259-30264. 10.1074/jbc.M401891200.CrossRefPubMed
43.
Zurück zum Zitat Whyteside AR, Turner AJ: Human neprilysin-2 (NEP2) and NEP display distinct subcellular localisations and substrate preferences. FEBS Lett. 2008, 582: 2382-2386. 10.1016/j.febslet.2008.05.046.CrossRefPubMed Whyteside AR, Turner AJ: Human neprilysin-2 (NEP2) and NEP display distinct subcellular localisations and substrate preferences. FEBS Lett. 2008, 582: 2382-2386. 10.1016/j.febslet.2008.05.046.CrossRefPubMed
44.
Zurück zum Zitat Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ: Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003, 40: 1087-1093. 10.1016/S0896-6273(03)00787-6.CrossRefPubMed Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ: Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003, 40: 1087-1093. 10.1016/S0896-6273(03)00787-6.CrossRefPubMed
46.
Zurück zum Zitat Farris W, Schutz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ: Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol. 2007, 171: 241-251. 10.2353/ajpath.2007.070105.PubMedCentralCrossRefPubMed Farris W, Schutz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ: Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol. 2007, 171: 241-251. 10.2353/ajpath.2007.070105.PubMedCentralCrossRefPubMed
47.
Zurück zum Zitat Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, Noda Y, Yamaguchi H, Nabeshima T, Saido TC, Iwata N: Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem. 2006, 281: 17941-17951. 10.1074/jbc.M601372200.CrossRefPubMed Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, Noda Y, Yamaguchi H, Nabeshima T, Saido TC, Iwata N: Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem. 2006, 281: 17941-17951. 10.1074/jbc.M601372200.CrossRefPubMed
48.
Zurück zum Zitat McDermott JR, Gibson AM: Degradation of Alzheimer’s beta-amyloid protein by human cathepsin D. Neuroreport. 1996, 7: 2163-2166. 10.1097/00001756-199609020-00021.CrossRefPubMed McDermott JR, Gibson AM: Degradation of Alzheimer’s beta-amyloid protein by human cathepsin D. Neuroreport. 1996, 7: 2163-2166. 10.1097/00001756-199609020-00021.CrossRefPubMed
49.
Zurück zum Zitat Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, Koster A, Hess B, Evers M, von Figura K, Peters C: Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. Embo J. 1995, 14: 3599-3608.PubMedCentralPubMed Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, Koster A, Hess B, Evers M, von Figura K, Peters C: Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. Embo J. 1995, 14: 3599-3608.PubMedCentralPubMed
Metadaten
Titel
Regulation of distinct pools of amyloid β-protein by multiple cellular proteases
verfasst von
Malcolm A Leissring
Anthony J Turner
Publikationsdatum
01.08.2013
Verlag
BioMed Central
Erschienen in
Alzheimer's Research & Therapy / Ausgabe 4/2013
Elektronische ISSN: 1758-9193
DOI
https://doi.org/10.1186/alzrt194

Weitere Artikel der Ausgabe 4/2013

Alzheimer's Research & Therapy 4/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.